Introduction
The use of post-thyroidectomy adjuvant radioactive iodine 131 ( 131 I) therapy is associated with dramatic decreases in locoregional recurrences, distant metastasis, and disease-related mortality in patients with differentiated thyroid carcinomas (DTC). 1 Although generally well tolerated, 131 I therapy is associated with substantial, albeit rare, side effects. While gastrointestinal problems, salivary and lacrimal gland complications, gonadal dysfunction, and second malignancies are well documented side effects of 131 I therapy, there is scant literature addressing nasolacrimal duct obstruction (NLDO). 2, 3 Different studies have mentioned that the incidence of NLDO was around 3% among DTC patients treated with 131 I therapy. The common presentation is an excessive overflow of tears (epiphora). Other signs and symptoms are the medial canthus mass, recurrent conjunctivitis, or infection (dacryocystitis). 4 In the Kingdom of Saudi Arabia, DTC has become the second most common malignancy, behind only breast cancer, accounting for more than 10% of all cancers among women. 5 The majority of these patients require adjuvant 131 I therapy at some point; only a small proportion of these patients can be at risk of 131 I therapy-acquired NLDO, which was the aim of our study. We also aimed to determine the correlation between NLDO and 131 I therapy along with other clinical and treatment parameters in DTC patients receiving 131 I therapy in our population.
Methods
After formal approval from the institutional ethics committee, the medical records of 864 patients, among a total of 1,192 patients, with confirmed DTC who were treated with 131 I therapy in two major tertiary care hospitals during the period from July 2000-December 2012 were reviewed using a computer-based institutional database system. Patients with NLDO were retrieved in the following manner:
• Demographic information (age at diagnosis and sex), as well as data regarding symptomatology, clinical procedures (anterior rhinoscopy and Jones fluorescein dye test), and 131 I therapy doses in millicurie (mCi) were collected.
• Information on the different diagnostic imaging modalities used, including dacryoscintigraphy, computed tomography (CT) dacryography of the neck, and fluorodeoxyglucose positron emission tomography, was collected.
• Data regarding the surgical intervention used, including balloon dilation, stenting, dacryocystorhinostomy (DCR), type of DCR (external or endoscopic endonasal), symptoms relief, and duration of relief were also recorded.
• Any discrepancies in data acquisition were resolved by directly questioning the patients and treating physicians (ear, nose, and throat, oncology, ophthalmology, and nuclear medicine).
• However, no attempt to systematize other associated sinonasal problems (potential confounders) of the patients was performed.
statistical analysis
The primary endpoint was the frequency of NLDO. All descriptive data were reported as the mean ± standard deviation, and percentages. The secondary endpoint was the correlation of NLDO with 131 I therapy (as tested by Pearson's correlation coefficients). Efforts were made to minimize the effects of potential confounders, which were controlled using multivariate analysis. Statistical analyses were performed using the computer program SPSS version 16.0. The Kaplan-Meier method was used to predict the cumulative risk of NLDO in our series. 
Results

Among
Discussion
Acquired NLDO secondary to 131 I therapy is an extremely rare complication in patients with DTC. In our cohort, the frequency of NLDO of 2.2% is consistent with other reported results ( Table 2) . [6] [7] [8] [9] [10] The incidence rate of NLDO in the general population is lacking, despite a detailed medical literature search. In the majority of cases, the diagnosis is made upon the basis of spontaneous reporting of epiphora by the patients. 6 This diagnostic delay leads to complete stenosis of the nasolacrimal ducts, and thus renders these patients to aggressive treatment. 6 In the clinical setting, the Jones fluorescein dye test is of significant value in NLDO patients. One Australian study has demonstrated that a negative The postulated mechanism for 131 I therapy-acquired NLDO is the direct uptake of 131 I in the nasolacrimal duct membrane epithelial cells via the sodium (Na+)/iodide (I) symporter (NIS) leading to radiation-induced cell damage (inflammation and fibrosis/stenosis). 9 The NIS is a membrane glycoprotein that mediates 131 I uptake in the thyroid gland and several other extrathyroid tissues (salivary glands, lacrimal glands, and ciliary body of the eye). 12 Recently, Morgenstern et al 13 have reported the overexpression of NIS in the nasolacrimal ducts using reverse transcriptase polymerase chain reaction and immunohistochemical analyses. In addition to the presence of sinonasal disease at the time of 131 I therapy, the treatment may theoretically further decrease the flow in the nasolacrimal ducts and thus increase the exposure to 131 I, which is secreted through the lacrimal system. I therapy; and 4) the bilateral nature of NLDO in most of cases. CT dacryography using diluted contrast medium was found to be an easy and highly sensitive tool to evaluate NLDO in our cohort, which endorsed the findings of Garcier et al. 15 Patients with incomplete NLDO have an excellent outlook with the use of balloon dilation and stenting, as complete recovery of symptoms is observed in 100% of cases. 3 Although the literature supports the hypothesis of complete symptom recovery with observation alone, in a few cases of incomplete NLDO, we did not find that observation was a feasible option. The reason for this can be explained by the fact that NLDO is possibly a chronic radiation-induced injury that progresses over a period of time. 16 The DCR success rate of 78.9% in our cohort is consistent with the findings of Fonseca et al. 6 However, the endoscopic endonasal DCR success rate of 60% is much inferior to that reported in the literature, which warrants more personnel training in this area in our region. 17 Because NLDO impairs the quality of life of a patient significantly, prevention of NLDO is a key issue. Currently, there is no mechanism available to stop the blockage of 131 I uptake in the nasolacrimal ducts via the NIS during 131 I therapy, 3 and there is scant data available regarding the prophylactic use of 2-(S)-(3-aminopropylamino) ethylphosphorothioic acid (amifostine) during 131 I therapy. 18 Further, the effectiveness of topical saline drops, nasolacrimal duct massage, Cumulative hazard probability
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Log-rank P=0.02 I therapy in patients with acute or chronic sinonasal problems as preventive measures needs to tested. Low 131 I therapy doses, whenever possible, can reduce the incidence of NLDO. 19 The limitations of our study were: 1) no systematic attempt to screen for NLDO or the presence of other potential confounders (sinonasal problems) was performed; and 2) the presence of possible selection and recall bias in our cohort.
Conclusion
In conclusion, NLDO following 131 I therapy in DTC patients is an under-recognized and rare complication, especially at higher 131 I doses (.150 mCi). A multidisciplinary approach (nuclear medicine/oncology, ear, nose, and throat, and ophthalmology) is very important in the prevention and treatment of NLDO.
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